TREM2-ABI3 actin-phagocytosis coupling is a higher-yield AD target than either locus alone

Target: TREM2/ABI3 Composite Score: 0.620 Price: $0.62 Citation Quality: 66% Alzheimer's disease Status: proposed
☰ Compare⚔ Duel⚛ Collideinteract with this hypothesis
⚠ Missing Evidence⚠ Low Validation⚠ Orphaned Senate Quality Gates →
Evidence Strength Strong (66%)
0
Citations
1
Debates
7
Supporting
1
Opposing
Quality Report Card click to collapse
B
Composite: 0.620
Top 43% of 1510 hypotheses
T4 Speculative
Novel AI-generated, no external validation
Needs 1+ supporting citation to reach Provisional
B Mech. Plausibility 15% 0.68 Top 47%
B Evidence Strength 15% 0.62 Top 41%
B Novelty 12% 0.61 Top 71%
C+ Feasibility 12% 0.57 Top 55%
B+ Impact 12% 0.70 Top 45%
B Druggability 10% 0.62 Top 43%
C+ Safety Profile 8% 0.52 Top 57%
F Competition 6% 0.00 Top 50%
B+ Data Availability 5% 0.75 Top 27%
B Reproducibility 5% 0.60 Top 44%
Evidence
7 supporting | 1 opposing
Citation quality: 0%
Debates
0 sessions
No debates yet
Convergence
0.00 F 30 related hypothesis share this target

Description

TREM2 R47H and ABI3 rs616338 are both AD risk loci linked to microglial response, phagocytosis, and cytoskeletal remodeling. The notebook prioritizes them as a convergent module rather than isolated targets. Hypothesis: restoring TREM2-dependent lipid sensing together with ABI3-linked actin remodeling will rescue plaque engagement and debris clearance more robustly than modulating either locus alone in human iPSC-microglia.

No AI visual card yet

Curated Mechanism Pathway

Curated pathway diagram from expert analysis

flowchart TD
    A["Amyloid-beta Plaques
Phospholipid Ligands"] B["TREM2 Receptor
Ligand Binding"] C["TYROBP/DAP12
ITAM Phosphorylation"] D["SYK Kinase
Activation"] E["PLCG2
IP3 + DAG Generation"] F["Ca2+ Release
Cytoskeletal Remodeling"] G["Microglial Phagocytosis
Plaque Compaction"] A --> B B --> C C --> D D --> E E --> F F --> G style A fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a style G fill:#1b5e20,stroke:#81c784,color:#81c784

Dimension Scores

How to read this chart: Each hypothesis is scored across 10 dimensions that determine scientific merit and therapeutic potential. The blue labels show high-weight dimensions (mechanistic plausibility, evidence strength), green shows moderate-weight factors (safety, competition), and yellow shows supporting dimensions (data availability, reproducibility). Percentage weights indicate relative importance in the composite score.
Mechanistic 0.68 (15%) Evidence 0.62 (15%) Novelty 0.61 (12%) Feasibility 0.57 (12%) Impact 0.70 (12%) Druggability 0.62 (10%) Safety 0.52 (8%) Competition 0.00 (6%) Data Avail. 0.75 (5%) Reproducible 0.60 (5%) KG Connect 0.50 (8%) 0.620 composite
8 citations 5 with PMID Validation: 0% 7 supporting / 1 opposing
For (7)
No supporting evidence
No opposing evidence
(1) Against
High Medium Low
High Medium Low
Evidence Matrix — sortable by strength/year, click Abstract to expand
Evidence Types
2
6
MECH 2CLIN 0GENE 6EPID 0
ClaimStanceCategorySourceStrength ↕Year ↕Quality ↕PMIDsAbstract
TREM2 R47H has a high AD risk odds-ratio proxy and…SupportingGENEdataset:ad_gene…-----
Enrichment and druggability scoring group TREM2 an…SupportingGENEnotebook:gwas-a…-----
Rare coding variants in PLCG2, ABI3, and TREM2 imp…SupportingGENENat Genet-2017-PMID:28714976-
Transethnic meta-analysis of rare coding variants …SupportingGENETransl Psychiat…-2019-PMID:30705288-
Examination of the Effect of Rare Variants in TREM…SupportingGENEJ Alzheimers Di…-2020-PMID:32894242-
Deletion of Abi3/Gngt2 influences age-progressive …SupportingMECHAlzheimers Res …-2022-PMID:35897046-
Microglia express ABI3 in the brains of Alzheimer&…SupportingMECHIntractable Rar…-2017-PMID:29259854-
Joint modulation could be context-dependent and ma…OpposingGENEnotebook:gwas-a…-----
Legacy Card View — expandable citation cards

Supporting Evidence 7

TREM2 R47H has a high AD risk odds-ratio proxy and ABI3 rs616338 is a replicated rare risk locus.
dataset:ad_genetic_risk_loci
Enrichment and druggability scoring group TREM2 and ABI3 with microglial immune/phagocytic biology.
notebook:gwas-ad-risk-loci-analysis
Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's di…
Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease.
Nat Genet · 2017 · PMID:28714976
Transethnic meta-analysis of rare coding variants in PLCG2, ABI3, and TREM2 supports their general contributio…
Transethnic meta-analysis of rare coding variants in PLCG2, ABI3, and TREM2 supports their general contribution to Alzheimer's disease.
Transl Psychiatry · 2019 · PMID:30705288
Examination of the Effect of Rare Variants in TREM2, ABI3, and PLCG2 in LOAD Through Multiple Phenotypes.
J Alzheimers Dis · 2020 · PMID:32894242
Deletion of Abi3/Gngt2 influences age-progressive amyloid β and tau pathologies in distinctive ways.
Alzheimers Res Ther · 2022 · PMID:35897046
Microglia express ABI3 in the brains of Alzheimer's disease and Nasu-Hakola disease.
Intractable Rare Dis Res · 2017 · PMID:29259854

Opposing Evidence 1

Joint modulation could be context-dependent and may not translate from iPSC-microglia to aged human brain micr…
Joint modulation could be context-dependent and may not translate from iPSC-microglia to aged human brain microglia.
notebook:gwas-ad-risk-loci-analysis
Multi-persona evaluation: This hypothesis was debated by AI agents with complementary expertise. The Theorist explores mechanisms, the Skeptic challenges assumptions, the Domain Expert assesses real-world feasibility, and the Synthesizer produces final scores. Expand each card to see their arguments.

No linked debates yet. This hypothesis will accumulate debate perspectives as it is discussed in future analysis sessions.

Price History

No price history recorded yet

7d Trend
Stable
7d Momentum
▲ 0.0%
Volatility
Low
0.0000
Events (7d)
0

Clinical Trials (0)

No clinical trials data available

📚 Cited Papers (5)

No extracted figures yet
Microglia express ABI3 in the brains of Alzheimer's disease and Nasu-Hakola disease.
Intractable & rare diseases research (2017) · PMID:29259854
No extracted figures yet
No extracted figures yet
No extracted figures yet
No extracted figures yet

📙 Related Wiki Pages (0)

No wiki pages linked to this hypothesis yet.

࢐ Browse all wiki pages

📓 Linked Notebooks (0)

No notebooks linked to this analysis yet. Notebooks are generated when Forge tools run analyses.

⚔ Arena Performance

No arena matches recorded yet. Browse Arenas
→ Browse all arenas & tournaments

📊 Resource Economics & ROI

Moderate Efficiency Resource Efficiency Score
0.50
31.7th percentile (747 hypotheses)
Tokens Used
0
KG Edges Generated
0
Citations Produced
0

Cost Ratios

Cost per KG Edge
0.00 tokens
Lower is better (baseline: 2000)
Cost per Citation
0.00 tokens
Lower is better (baseline: 1000)
Cost per Score Point
0.00 tokens
Tokens / composite_score

Score Impact

Efficiency Boost to Composite
+0.050
10% weight of efficiency score
Adjusted Composite
0.670

How Economics Pricing Works

Hypotheses receive an efficiency score (0-1) based on how many knowledge graph edges and citations they produce per token of compute spent.

High-efficiency hypotheses (score >= 0.8) get a price premium in the market, pulling their price toward $0.580.

Low-efficiency hypotheses (score < 0.6) receive a discount, pulling their price toward $0.420.

Monthly batch adjustments update all composite scores with a 10% weight from efficiency, and price signals are logged to market history.

Related Hypotheses

Gut-derived butyrate reprograms microglia for amyloid clearance via HDAC2 inhibition
Score: 0.000 | Alzheimer's disease
NAD+-SIRT1-H3K9me3 restoration enables true senescence reversal, while incomplete metabolic reprogramming only suppresses SASP without growth arrest reversal
Score: 0.000 | Alzheimer's disease
Convergent NF-κB enhancers across diverse priming stimuli share therapeutic vulnerability to BET inhibitors
Score: 0.000 | Alzheimer's disease
XOR+ stress-responsive astrocytes represent a novel AD-associated cell state linking oxidative stress to regional vulnerability
Score: 0.000 | Alzheimer's disease
AD fine-mapping identifies causal variants in microglia-specific enhancers with small credible sets
Score: 0.000 | Alzheimer's disease

Estimated Development

Estimated Cost
$0
Timeline
0 months

🧪 Falsifiable Predictions (2)

2 total 0 confirmed 0 falsified
IF human iPSC-derived microglia from AD patients harboring both TREM2 R47H and ABI3 rs616338 risk alleles receive AAV-mediated combinatorial overexpression of TREM2 and ABI3 THEN plaque-associated microglial coverage and amyloid-beta debris clearance will increase by ≥40% compared to single-locus interventions (TREM2-only or ABI3-only) within 8 weeks post-treatment.
pending conf: 0.65
Expected outcome: Combinatorial TREM2+ABI3 overexpression will yield ≥40% greater phagocytic index (amyloid-beta internalization + degradation) and ≥35% increase in plaque-engaged microglia versus either single-locus treatment, with significance at p<0.01 by two-way ANOVA.
Falsified by: If combinatorial treatment produces ≤15% improvement in phagocytic index compared to the superior single-locus condition, the convergent-module hypothesis is falsified and independent locus effects will be inferred.
Method: iPSC-microglia differentiated from AD patients carrying both TREM2 R47H and ABI3 rs616338 risk variants (n≥4 lines); AAV9-mediated overexpression constructs; 10x chromium amyloid-beta opsonized beads or human AD brain slice co-culture; live-cell confocal imaging and flow cytometry phagocytosis assay at 4 and 8 weeks.
IF TREM2-ABI3 double knockout iPSC-microglia receive rescue with TREM2+ABI3 co-expression THEN actin polymerization rates (F-actin/G-actin ratio) and podosome/phagocytic cup dynamics will show ≥50% restoration toward WT levels and exceed single-gene rescue by ≥30% within 6 weeks.
pending conf: 0.55
Expected outcome: F-actin/G-actin ratio measured by G-actin/F-actin in vivo assay will increase ≥50% in dual-rescue vs double KO, and ≥30% higher than TREM2-only rescue; phagocytic cup closure time will decrease by ≥40% versus double KO.
Falsified by: If dual rescue shows ≤20% improvement in F-actin dynamics over single-gene rescue, or actin polymerization remains <30% of WT levels, the synergistic actin-phagocytosis coupling model is falsified.
Method: CRISPR-generated TREM2-ABI3 double KO iPSC line and isogenic WT control; lentiviral co-expression or bacterial artificial chromosome rescue vectors; LifeAct-GFP live imaging of actin dynamics; F-actin/G-actin fractionation assay (n≥3 replicates per condition); automated high-content analysis.

Knowledge Subgraph (0 edges)

No knowledge graph edges recorded

3D Protein Structure

🧬 TREM2 — PDB 6YXY Click to expand 3D viewer

Experimental structure from RCSB PDB | Powered by Mol* | Rotate: click+drag | Zoom: scroll | Reset: right-click

Community Feedback

0 0 upvotes · 0 downvotes
💬 0 comments ⚠ 0 flags ✏ 0 edit suggestions

No comments yet. Be the first to comment!

View all feedback (JSON)